Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting
ConditionExudative Macular Degeneration
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age50-100
SponsorMedical University of Vienna
About this trial
The purpose of this study is to implement quantitative assessment tools for the treatment of active neovascular AMD patients in a real-world setting in order to provide advantages for both patients (treatment burden) and healthcare system (scheduling visits/treatments).
Eligibility criteria
Qualifiers
Adults ≥ 50 years
Active neovascular AMD (classic, occult choroidal neovascularization (CNV), RAP lesion or PCV lesion) assessed by OCT, OCTA, FA
Patients who have a BCVA score better or equal 0.1 (20/200) in the study eye using ETDRS
No significant fibrosis or geographic atrophy (GA) involving the fovea
Disqualifiers
Hypersensitivity to Fluoresceine, Ranibizumab, Aflibercept, Brolucizumab or to any of the excipients (Polysorbate 20, Sodium dihydrogen phosphate, monohydrate, Disodium hydrogen phosphate, heptahydrate, Sodium chloride, Sucrose)
Any surgical treatment of the eye within 3 months prior to baseline in the study eye
History of pseudophakic cystoid macular edema (Irvine Gass Syndrome)
History of glaucoma filtration surgery, corneal transplant surgery or extracapsular extraction of cataract with phacoemulsification within six months preceding Visit 0, or a history of post-operative complications within the last 12 months preceding Visit 0 in the study eye (uveitis, cyclitis etc.)
Trial design
Treatments tested in this trial
- anti-VEGF agent
- anti-VEGF agent
Treatment groups
290 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov